šŸ“Š This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Apogee Therapeutics

1.1 - Company Overview

Apogee Therapeutics Logo

Apogee Therapeutics

Headquarter: United States
Founded: 20XXšŸ”’
Employees: 100-500šŸ”’
šŸŒ Website

Company description

  • Provider of antibody therapeutics for immunological and inflammatory disorders, including APG777 targeting IL-13 for atopic dermatitis, APG808 targeting IL-4RĪ± for chronic obstructive pulmonary disease, APG990 targeting OX40L for atopic dermatitis (preclinical), and APG222 dual-inhibiting OX40L and IL-13 for atopic dermatitis; designed for extended half-life and potentially less frequent dosing.

Products and services

  • APG777: An antibody therapeutic targeting IL-13 for atopic dermatitis, engineered for extended half-life and potentially less frequent dosing
  • APG808: An antibody therapeutic targeting IL-4RĪ± for chronic obstructive pulmonary disease, developed for extended half-life and potentially less frequent dosing
  • APG222: A preclinical dual-inhibition antibody therapeutic targeting both OX40L and IL-13 for atopic dermatitis, unifying dual targets in one therapy

Key contacts

šŸ”’
šŸ”’

Financial details

šŸ”’

1.2 - Competitors and similar companies to Apogee Therapeutics

Hansa Biopharma Logo

Hansa Biopharma

HQ: Sweden Website
  • Description: Provider of immunomodulatory treatments for rare immunological diseases, including Imlifidase, a first-generation IgG-cleaving enzyme for rapid inactivation of IgG antibodies via single intravenous treatment. Offers a proprietary enzyme technology platform targeting pathogenic antibodies across transplantation, autoimmunity, gene therapy and oncology, supported by strategic partnerships and sustainability initiatives.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Hansa Biopharma company profile ā†’
Fumapharm Logo

Fumapharm

HQ: Switzerland Website
  • Description: Provider of pharmaceuticals as a privately held company.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Fumapharm company profile ā†’
Citryll Logo

Citryll

HQ: The Netherlands Website
  • Description: Provider of pharmaceutical drugs targeting Neutrophil Extracellular Traps (NETs) to treat autoimmune and inflammatory diseases such as SLE, RA, vasculitis, and IPF. Offers CIT-013, a therapeutic antibody; conducts NETosis inhibition research to reduce auto-antigen release and clear pro-inflammatory NETs; advances clinical development with first-in-human and planned Phase 2a trials in RA and hidradenitis suppurativa; and pursues collaboration opportunities.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Citryll company profile ā†’
Sparrow Pharmaceuticals Logo

Sparrow Pharmaceuticals

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical therapies for disorders of corticosteroid excess, including SPI-62, an oral HSD-1 inhibitor designed to reduce intracellular cortisol in conditions like endogenous Cushingā€™s syndrome and autonomous cortisol secretion, and SPI-47, combining SPI-62 with prednisolone for autoimmune diseases such as polymyalgia rheumatica.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full Sparrow Pharmaceuticals company profile ā†’
NorthSea Therapeutics Logo

NorthSea Therapeutics

HQ: The Netherlands Website
  • Description: Provider of first-in-class, oral, structurally engineered lipid therapeutics leveraging Structurally Engineered Fatty Acid (SEFA) technology to target metabolic, inflammatory and fibrotic diseases. Pipeline includes Icosabutate (Phase 2b for NASH), SEFA-1024 (Phase 1 for severe hypertriglyceridemia), and SEFA-6179 (Phase 1 for intestinal failure-associated liver disease).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ā—ā—ā—ā—ā—
  • Total funding raised: $ā—ā—ā—m
  • Backers: ā—ā—ā—ā—ā—ā—ā—ā—ā—ā—
  • Acquisitions: ā—ā—
View full NorthSea Therapeutics company profile ā†’
šŸ”’

2.M&A buyers

2.1 Potential strategic acquirers in the sector

šŸ”’
šŸ”’
šŸ”’
šŸ”’ View all strategic buyers with complete profiles
Start Free Trial ā†’

2.2 - Strategic buyer groups for Apogee Therapeutics

šŸ”’

Buyer group 1: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 2: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”’

Buyer group 3: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ

ā—ā— companies
Description: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
Key Products: ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ
šŸ”’ View all companies in this group
Request Free Trial Now ā†’
šŸ”“ Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial ā†’

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Apogee Therapeutics

2.2 - Growth funds investing in similar companies to Apogee Therapeutics

šŸ”’ View all growth equity funds with complete profiles
Start Free Trial ā†’

4 - Top valuation comps for Apogee Therapeutics

4.2 - Public trading comparable groups for Apogee Therapeutics

šŸ”“ Unlock all public trading comparable groups with complete valuation data
Start Free Trial ā†’

4.3 - M&A Transactions similar to Apogee Therapeutics

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
šŸ”’ View all M&A transactions with complete deal terms
Request Free Trial Now ā†’

Frequently Asked Questions

About Apogee Therapeutics

What does Apogee Therapeutics do?

Apogee Therapeutics is a provider of antibody therapeutics for immunological and inflammatory disorders, including APG777 targeting IL-13 for atopic dermatitis, APG808 targeting IL-4RĪ± for chronic obstructive pulmonary disease, APG990 targeting OX40L for atopic dermatitis (preclinical), and APG222 dual-inhibiting OX40L and IL-13 for atopic dermatitis; designed for extended half-life and potentially less frequent dosing.

Who are Apogee Therapeutics's competitors?

Apogee Therapeutics's competitors and similar companies include Hansa Biopharma, Fumapharm, Citryll, Sparrow Pharmaceuticals, and NorthSea Therapeutics.

Where is Apogee Therapeutics headquartered?

Apogee Therapeutics is headquartered in United States.

How many employees does Apogee Therapeutics have?

Apogee Therapeutics has 1,000 employees šŸ”’.

When was Apogee Therapeutics founded?

Apogee Therapeutics was founded in 2010 šŸ”’.

What sector and industry vertical is Apogee Therapeutics in?

Apogee Therapeutics is in the Enterprise Software šŸ”’ sector and industry

M&A Buyers & Acquirers for Apogee Therapeutics

Who are the top strategic acquirers in Apogee Therapeutics's sector and industry

Top strategic M&A buyers and acquirers in Apogee Therapeutics's sector include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which M&A buyer groups are most relevant for Apogee Therapeutics?

Top strategic M&A buyers groups and sectors for Apogee Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ , ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Financial Investors investing in Apogee Therapeutics's sector and industry vertical

Which are the top PE firms investing in Apogee Therapeutics's sector and industry vertical?

Top PE firms investing in Apogee Therapeutics's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top buyout funds acquiring in Apogee Therapeutics's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Apogee Therapeutics's sector and industry vertical include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Who are the top growth equity funds investing in companies in Apogee Therapeutics's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Apogee Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Valuation benchmarks of companies in Apogee Therapeutics's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Apogee Therapeutics?

The key public trading comparables and valuation benchmarks for Apogee Therapeutics include ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ, and ā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆā–ˆ šŸ”’.

Which are the key trading comparable groups for Apogee Therapeutics for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Apogee Therapeutics with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Apogee Therapeutics's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Apogee Therapeutics with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Apogee Therapeutics's' sector and industry vertical?

Access recent funding rounds and capital raises in Apogee Therapeutics's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Apogee Therapeutics